CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.88
+9.04%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.82
From 52W high−65.00%
Volume519004.00
Market cap$135.71M
P/E (TTM)—
P/S (TTM)2.7x
Div yield—
Key dataNov 4, 2026
Open
$0.82
From 52W high
−65.00%
Volume
519004.00
Market cap
$135.71M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
34.9
MomentumView details →
1D Return
+9.04%
YTD Return
−43.93%
SummaryUpdated Jun 1, 2026
Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company founded in 2010 and headquartered in Redwood City, California. Originally established as BioGenerics, Inc., the company changed its name to Coherus BioSciences in April 2012 and went public in November 2014. The company has undergone a significant strategic transformation, evolving from a biosimilar-focused business to an innovative oncology company. Following the divestiture of its biosimilar assets in 2024-2025, Coherus now concentrates exclusively on developing and commercializing novel cancer treatments, particularly focusing on immuno-oncology therapies that target the tumor microenvironment.
Similar companies
Latest newsMore news →
Coherus Oncology announced interim clinical data from its TREGCHECK program evaluating tagmokitug with toripalimab, with or without chemotherapy, including a confirmed 75% objective response rate in evaluable first-line ESCC patients regardless of PD-L1 status and 100% among PD-L1-positive patients.7d agoCoherus Oncology announced that it will release its third-quarter 2026 financial results on November 9, 2026, and hold a conference call and webcast that day.9d agoCoherus Oncology announced that it will release interim tagmokitug clinical data and host a webcast on October 28, 2026.21d ago